An open-label multicenter study to assess the efficacy and safety of daily oral administration of 5 and 10mg VESIcare (solifenacin succinate) in patients who wish to switch from Detrol LA (tolterodine tartrate extended release) for the treatment of overactive bladder symptoms versus: VESIcare efficacy and research study US

Trial Profile

An open-label multicenter study to assess the efficacy and safety of daily oral administration of 5 and 10mg VESIcare (solifenacin succinate) in patients who wish to switch from Detrol LA (tolterodine tartrate extended release) for the treatment of overactive bladder symptoms versus: VESIcare efficacy and research study US

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs Solifenacin (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms VERSUS
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 12 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top